Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;69(100):S11–S15.
McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med. 2003;4(suppl 5):S3–S9.
Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the US Food and Drug Administration (Erratum published in Radiology. 1997;204[3]:876). Radiology. 1997;203(3):605–610.
Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent–induced nephropathy by hemofiltration. N Engl J Med. 2003;349(14):1333–1340.
Hossain MA, Costanzo E, Cosentino J, et al. Contrast-induced nephropathy: pathophysiology, risk factors, and prevention. Saudi J Kidney Dis Transpl. 2018;29(1):1–9. doi:10.4103/1319-2442.225199
Walsh SR, Tang T, Gaunt ME, Boyle JR. Contrast-induced nephropathy. J Endovasc Ther. 2007;14(1):92–100.
Azzalini L, Spagnoli V, Ly HQ. Contrast-induced nephropathy: from pathophysiology to preventive strategies. Can J Cardiol. 2016;32(2):247–255.
Solomon R, Deray G, Consensus Panel for CIN. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl. 2006;69(100):S51–S53. doi:10.1038/sj.ki.5000375
Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):59K–77K.
Briguori C, Marenzi G. Contrast-induced nephropathy: pharmacological prophylaxis. Kidney Int Suppl. 2006;69(100):S30–S38.
Goic JB, Koenigshof AM, McGuire LD, Klinger AC, Beal MW. A retrospective evaluation of contrast-induced kidney injury in dogs (2006–2012). J Vet Emerg Crit Care (San Antonio). 2016;26(5):713–719.
Pollard RE, Puchalski SM, Pascoe PJ. Hemodynamic and serum biochemical alterations associated with intravenous administration of three types of contrast media in anesthetized dogs. Am J Vet Res. 2008;69(10):1268–1273.
Tumlin J, Stacul F, Adam A, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A): 14K–20K.
14. IRIS staging of CKD. International Renal Interest Society. Accessed April 10, 2020. www.iris-kidney.com/guidelines/staging.html
15. Weisse C. Fundamentals of interventional radiology and interventional endoscopy. In: Johnston S, Tobias K, eds. Veterinary Surgery: Small Animal. 2nd ed. Elsevier; 2018:309–317.
Advertisement
During the same week, 3 sequential patients (a 10-year-old 8.7-kg spayed female poodle cross [dog 1], 13-year-old 2.6-kg spayed female domestic longhair cat, and 13-year-old 9.0-kg castrated male mixed-breed dog [dog 2]) underwent CT-angiography (day 0) and transarterial embolization (day 1) for nonresectable hepatocellular carcinoma (n = 2) or prostatic carcinoma (1).
Contrast-induced nephropathy (CIN) was suspected in all animals on the basis of higher serum creatinine concentrations after contrast medium administration (exposure), compared with baseline concentrations before exposure, consistent with CIN definitions. The total dose of contrast medium was < 3 mL/kg for each exposure. For all 3 patients, creatinine concentration peaked at a median of 3 days (range, 2 to 3 days) after the first exposure (day 0), and the median absolute and relative increases in creatinine concentration after exposure (vs baseline concentrations before exposure) were 2.9 mg/dL (range, 2.2 to 3.7 mg/dL) and 410% (range, 260 to 720%), respectively.
The patients received individually tailored supportive care for acute kidney injury. Serum creatinine concentrations began to improve at a median of 4 days (range, 3 to 4 days) and returned to within reference limits at a median of 7 days (range, 3 to 13 days) following initial exposure.
CIN should be considered as a potential complication following IV administration of contrast medium. Short-term outcome following CIN can be excellent with supportive care.